Highbridge Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Highbridge Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-20,904	Closed	-$339K	–	1656
2016 Q3	$339K	Buy	+20,904	New	+$304K	0.01%	965
2016 Q1	–	Sell	-6,047	Closed	-$207K	–	1873
2015 Q4	$207K	Buy	+6,047	New	+$210K	﹤0.01%	1340
2015 Q3	–	Sell	-17,904	Closed	-$573K	–	1872
2015 Q2	$573K	Buy	+17,904	New	+$460K	0.01%	903

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Highbridge Capital Management's RVNC Position: Q4 2016 in Review

Highbridge Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2016, closing a stake of 20,904 shares — an estimated $339K sold.

Highbridge Capital Management first reported a position in RVNC in Q2 2015 and held it in 3 quarters. The position peaked at $573K in Q2 2015. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

Highbridge Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 20,904 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $339K.
Highbridge Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
Highbridge Capital Management's Revance Therapeutics, Inc. position peaked at $573K in Q2 2015.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.